Xintian Pharmaceutical: Plans to establish up to 50 new branches.

The New Tian Pharmaceutical announced that the board of directors meeting held on June 15, 2026, approved the proposal to increase the number of subsidiaries from "not more than 30" to "not more than 50", mainly responsible for product clinical research, brand strategy, and marketing. This matter is within the approval authority of the board of directors and does not involve related party transactions or major asset restructuring. The establishment of the number and scope of operations has uncertainties and still needs approval from the industry and commerce department and registration procedures. This move is in line with the company's planning and is expected to enhance its overall strength, but managing subsidiaries in different locations poses challenges, so the company will strengthen control.